Pascal Hammel

3.5k citations

22 papers · 2.1k · 2 hit papers · h-index 12

Impact in

Oncology top 1%
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Cancer Research top 2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 18
- Pancreatic and Hepatic Oncology Research 13
- PARP inhibition in cancer therapy 8
Pulmonary and Respiratory Medicine 7
- Advanced Breast Cancer Therapies 5
- Renal cell carcinoma treatment 2

Co-authors: Eric Van Cutsem (16 shared papers)Teresa Macarulla (14 shared papers)Michele Reni (11 shared papers)Talia Golan (13 shared papers)Michael J. Hall (11 shared papers)Daniel Hochhauser (10 shared papers)Do‐Youn Oh (9 shared papers)Hedy L. Kindler (10 shared papers)
Journals: Journal of Clinical Oncology (14 papers)New England Journal of Medicine (2 papers)Cancers (1 paper)Cancer Treatment Reviews (1 paper)International Journal of Cancer (1 paper)
Partner nations: France United States Germany

In The Last Decade

Pascal Hammel

22 papers receiving 2.1k citations

Pascal Hammel's Hit Papers

align trajectories log scale

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 2022 · 128 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Journal of Clinical Oncology
2019 New England Journal of Medicine

Peers

Countries citing papers authored by Pascal Hammel

Since Specialization

Citations

This map shows the geographic impact of Pascal Hammel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Hammel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Hammel more than expected).

Fields of papers citing papers by Pascal Hammel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Hammel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Hammel. The network helps show where Pascal Hammel may publish in the future.

Co-authors

The 25 scholars most cited alongside Pascal Hammel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pascal Hammel Line = papers co-authored together Pascal Hammel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer New England Journal of Medicine ·Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler Hit paper breakdown →	2019	1530
2	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer Journal of Clinical Oncology ·Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan Hit paper breakdown →	2022	128
3	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). Journal of Clinical Oncology ·Margaret A. Tempero, Eric Van Cutsem, Darren Sigal, Do‐Youn Oh, Nicola Fazio, Teresa Macarulla, Erika Hitre, Pascal Hammel, Andrew Hendifar, Susan E. Bates, Chung‐Pin Li, Christelle de la Fouchardière, Volker Heinemann, Anthony Maraveyas, Nathan Bahary, Laura Layos, Vaibhav Sahai, Lei Zheng, Jill Lacy, Andrea J. Bullock, (unknown)	2020	96
4	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer International Journal of Cancer ·Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon, Teresa Macarulla, I. Bazin, Elena Poddubskaya, Nebojša Manojlović, Dejan Radenković, Chris Verslype, Éric Raymond, Antonio Cubillo, Armin Schueler, Charles Zhao, Pascal Hammel	2018	75
5	Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Journal of Clinical Oncology ·Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler	2021	59
6	Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial Journal of Clinical Oncology ·Talia Golan, Hedy L. Kindler, Joon Oh Park, Michele Reni, Teresa Macarulla, Pascal Hammel, Eric Van Cutsem, Dirk Arnold, Daniel Hochhauser, David McGuinness, Gershon Y. Locker, Teodora Goranova, Philipp Schatz, Yuzhen Liu, Michael J. Hall	2020	50
7	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence Cancer Treatment Reviews ·Thomas Seufferlein, Pascal Hammel, Jean‐Robert Delpéro, Teresa Macarulla, Per Pfeiffer, Gerald W. Prager, Michele Reni, Massimo Falconi, Philip A. Philip, Eric Van Cutsem	2019	42
8	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. Journal of Clinical Oncology ·David Goldstein, Robert Hassan El Maraghi, Pascal Hammel, Volker Heinemann, Volker Kunzmann, Javier Sastre, Werner Scheithauer, Salvatore Siena, Josep Tabernero, Luís Teixeira, Giampaolo Tortora, Jean‐Luc Van Laethem, Rosemary Young, Xinyu Wei, Brian Lu, Alfredo Romano, Daniel D. Von Hoff	2014	28
9	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer. Journal of Clinical Oncology ·Eric Van Cutsem, Manuel Hidalgo, I. Bazin, Jean-Luc Canon, Elena Poddubskaya, Nebojša Manojlović, Michèle Milella, Dejan Radenković, Chris Verslype, Wei Guo, Lars Damstrup, Pascal Hammel	2015	19
10	Targeting DNA Damage Repair Mechanisms in Pancreas Cancer Cancers ·Lukas Perkhofer, Talia Golan, Pieter‐Jan Cuyle, Tamara Matysiak‐Budnik, Jean–Luc Van Laethem, Teresa Macarulla, Estelle Cauchin, Alexander Kleger, Alica K. Beutel, Johann Gout, Albrecht Stenzinger, Eric Van Cutsem, Joaquim Bellmunt, Pascal Hammel, Eileen M. O’Reilly, Thomas Seufferlein	2021	18
11	Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). Journal of Clinical Oncology ·Talia Golan, Hedy L. Kindler, Joon Oh Park, Michele Reni, T. Macarulla Mercadé, Pascal Hammel, Eric Van Cutsem, Dirk Arnold, Daniel Hochhauser, Gershon Y. Locker, Michael J. Hall	2018	12
12	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC). Journal of Clinical Oncology ·David Goldstein, Robert H. El-Maraghi, Pascal Hammel, Volker Heinemann, Volker Kunzmann, Javier Sastre, Werner Scheithauer, Salvatore Siena, Teresa Macarulla, Luís Teixeira, Giampaolo Tortora, Jean‐Luc Van Laethem, Darryl Penenberg, Brian Lu, Alfredo Romano, Daniel D. Von Hoff	2014	11
13	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. Journal of Clinical Oncology ·Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, T. Macarulla Mercadé, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Talia Golan	2019	10
14	Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake Therapeutic Advances in Medical Oncology ·Talia Golan, Raffaella Casolino, Andrew V. Biankin, Pascal Hammel, Kristen Whitaker, Michael J. Hall, Douglas L. Riegert‐Johnson	2023	10
15	Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma. PubMed ·Talia Golan, Pascal Hammel	2021	4
16	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. Journal of Clinical Oncology ·Michael J. Hall, Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Seongjung Joo, Hyun Kyoo Yoo, Nikunj Patel, Hedy L. Kindler	2020	3
17	TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). Journal of Clinical Oncology ·Pascal Hammel, Rossana Berardi, G.J. Creemers, Antonio Cubillo, Eric Van Cutsem, Richard Greil, Teresa Macarulla, Jean‐Philippe Metges, Marcus Smith Noel, Peter Nygren, Pia Österlund, Thomas Seufferlein, Harpreet Wasan, Anu Gupta, Linda Marie Grummer, Nigel Biswas–Baldwin, Richard Kay, Hagop Youssoufian, Iman El‐Hariry, Manuel Hidalgo	2020	3
18	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P). Journal of Clinical Oncology ·Teresa Macarulla, Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Talia Golan	2020	1
19	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). Journal of Clinical Oncology ·Lawrence H. Schwartz, Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, J. Fromageau, Dana Ghiorghiu, David McGuinness, Gershon Y. Locker, Talia Golan	2021	1
20	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial. Journal of Clinical Oncology ·Michele Reni, Hedy L. Kindler, Pascal Hammel, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Talia Golan	2020	1

About Pascal Hammel

Pascal Hammel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Economics and Econometrics and Molecular Biology, having authored 22 papers that have together received 2.1k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (13 papers), PARP inhibition in cancer therapy (8 papers), Cancer Genomics and Diagnostics (6 papers), Advanced Breast Cancer Therapies (5 papers), Economic and Financial Impacts of Cancer (3 papers), DNA Repair Mechanisms (2 papers), Renal cell carcinoma treatment (2 papers) and BRCA gene mutations in cancer (2 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (666 citations), Pulmonary and Respiratory Medicine (306 citations), Molecular Biology (577 citations) and Pathology and Forensic Medicine (115 citations). Pascal Hammel has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Eric Van Cutsem, Teresa Macarulla, Michele Reni, Talia Golan, Michael J. Hall, Daniel Hochhauser, Do‐Youn Oh, Hedy L. Kindler, David McGuinness and Gershon Y. Locker. Their work appears in journals such as Journal of Clinical Oncology, New England Journal of Medicine, Cancers, Cancer Treatment Reviews and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Pascal Hammel

Impact in

Papers in i

In The Last Decade

Pascal Hammel

Pascal Hammel's Hit Papers

Peers

Countries citing papers authored by Pascal Hammel

Fields of papers citing papers by Pascal Hammel

All Works

About Pascal Hammel

Explore authors with similar magnitude of impact

Papers in